# Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

> **NCT02254785** · PHASE2 · UNKNOWN · sponsor: **British Columbia Cancer Agency** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostatic Cancer

## Interventions

- **DRUG:** cabazitaxel
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide 160mg daily (oral)

## Key facts

- **NCT ID:** NCT02254785
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2020-05
- **Final completion:** 2020-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254785, "Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02254785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*